FDA APPROVES TREATMENT FOR HAIRY CELL LEUKEMIA

By | May 3, 2017

FDA approves new kind of treatment for hairy cell leukemia

Sep 13, 2018 · “Lumoxiti fills an unmet need for patients with hairy cell leukemia whose disease has progressed after trying other FDA-approved therapies,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.
Continue

FDA approves treatment for ‘hairy cell’ leukemia – UPI.com

The FDA has approved a treatment for some case of "hairy cell" leukemia, the agency announced on Thursday. Photo by EmilianDanaila/Pixabay FRIDAY, Sept. 14, 2018 — Lumoxiti injection has been approved to treat certain instances of relapsed or refractory "hairy cell" leukemia, or HCL, the U.S. Food and Drug Administration said Thursday.
Continue

FDA approves novel treatment for hairy cell leukemia

FDA approves novel treatment for hairy cell leukemia September 15, 2018 (HealthDay)—Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia (HCL), the U.S. Food and Drug Administration said yesterday.
Continue

FDA Approves AstraZeneca’s Treatment for Hairy Cell Leukemia

The FDA approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Continue

FDA Approves New Treatment for Hairy Cell Leukemia

Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research is quoted in the approval as stating, "[Moxetumomab pasudotox] fills an unmet need for patients with hairy cell leukemia whose disease has progressed after trying other FDA-approved therapies.
Continue

FDA approves new kind of treatment for hairy cell leukemia

FDA approved on September 13 moxetumomab pasudotox-tdfk (Lumoxiti—AstraZeneca) injection for the treatment of hairy cell leukemia (HCL). The drug, a CD22-directed cytotoxin, is approved to treat adults with relapsed or refractory HCL who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Continue

FDA Approves Novel Treatment for Hairy Cell Leukemia

FDA Approves Novel Treatment for Hairy Cell Leukemia Print this page FRIDAY, Sept. 14, 2018 — Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia (HCL), the U.S. Food and Drug Administration said yesterday.
Continue

FDA Approves New Treatment for Hairy Cell Leukemia

The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Continue

Moxetumomab Approved for Hairy Cell Leukemia – National

FDA has approved moxetumomab pasudotox (Lumoxiti), a bacterial toxin–based drug, for the treatment of hairy cell leukemia (HCL). The approval covers the use of moxetumomab in patients with HCL who have already undergone standard treatments.
Continue

FDA Approves New Agent for Hairy Cell Leukemia

The Food and Drug Administration (FDA) approved the use of Lumoxiti (moxetumomab pasudotox-tdfk) for patients with relapsed or refractory hairy cell leukemia (HCL) who previously had at least two prior systemic therapies, including treatment with a purine nucleoside analog. The Food and Drug
Continue

Category: Uncategorized